Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Brigitte Robertson"'
Publikováno v:
Drugs in R&D, Vol 19, Iss 2, Pp 167-175 (2019)
Abstract Background and objective SHP465 mixed amphetamine salts extended release is a once-daily, single-entity, mixed amphetamine salts capsule product for attention-deficit/hyperactivity disorder. The objective of this study was to evaluate amphet
Externí odkaz:
https://doaj.org/article/71cb3852fdf343deaac91e8d2e5c9930
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objectives: In two studies of adult attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release significantly reduced ADHD-Rating Scale, 4th Edition total score (ADHD-RS-IV-TS) versus placebo (PBO). This rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99adf38e4a06321a8826502bb290b6d6
http://europepmc.org/articles/PMC7475095
http://europepmc.org/articles/PMC7475095
Autor:
Michael Huss, Sepehr Farahbakhshian, Brigitte Robertson, Caleb Bliss, Tamara Werner-Kiechle, David R Coghill
Publikováno v:
European Child & Adolescent Psychiatry
Several recent phase 3 clinical trials of attention-deficit/hyperactivity disorder (ADHD) medications have used the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). Here, we assess WFIRS-P response in individual patients in two pivot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1bc967857fc9237aa2c15c505fb7e4d
http://europepmc.org/articles/PMC8060241
http://europepmc.org/articles/PMC8060241
Autor:
Daniel F. Connor, Tamara Werner-Kiechle, Brigitte Robertson, Jeffrey H. Newcorn, Michael Huss, Amaia Hervás
Publikováno v:
Journal of Developmental & Behavioral Pediatrics. 41:565-570
OBJECTIVE To assess the efficacy of the non-stimulant guanfacine extended release (GXR) on attention-deficit/hyperactivity disorder (ADHD) symptoms in children and adolescents, with and without comorbid oppositional defiant disorder (ODD). METHODS Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c2c09787027bf88ccdfd86e5e6a089
https://doi.org/10.1097/dbp.0000000000000822
https://doi.org/10.1097/dbp.0000000000000822
Autor:
Yi Wang, Patrick Martin, James Wu, Ann C. Childress, Robert L. Findling, Brigitte Robertson, Scott H. Kollins
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objectives: Describe the safety and tolerability of lisdexamfetamine dimesylate (LDX) and provide data on clinical effects for efficacy-related endpoints and pharmacokinetics in preschool-aged children with attention-deficit/hyperactivity disorder (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dccd3782564157d1a9deeb34da33f9bb
https://doi.org/10.1089/cap.2019.0117
https://doi.org/10.1089/cap.2019.0117
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objectives: In a previous pivotal study of children and adolescents (aged 6–17 years) with attention-deficit/hyperactivity disorder (ADHD), dose-optimized SHP465 mixed amphetamine salts (MAS) extended-release (12.5–25 mg once daily) was superior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2869ecc37c9047c465784f1303daab62
https://pubmed.ncbi.nlm.nih.gov/33185468
https://pubmed.ncbi.nlm.nih.gov/33185468
Publikováno v:
Journal of Attention Disorders
Objective: Assess executive function (EF) improvement with SHP465 mixed amphetamine salts (MAS) extended-release in adults with attention-deficit/hyperactivity disorder (ADHD) using responder analyses of the Brown Attention-Deficit Disorder Scale (BA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb99e761b34070f6c44c2164e8de17a6
https://pubmed.ncbi.nlm.nih.gov/33150816
https://pubmed.ncbi.nlm.nih.gov/33150816
Autor:
Bryan Dirks, Jeffrey H. Newcorn, Brigitte Robertson, Michael Huss, J. Antoni Ramos-Quiroga, Joan Gu
Publikováno v:
European Child & Adolescent Psychiatry. 27:1283-1294
Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Participants received dose-optimized GXR (1–7 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74be51922c51b1ce8f89fed042919e7d
https://doi.org/10.1007/s00787-018-1113-4
https://doi.org/10.1007/s00787-018-1113-4
Autor:
Margo Jaffee, Ann C. Childress, Brigitte Robertson, Brian Yan, Ming Yu, Michael S. Greenbaum, Matthew Brams
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objective: The aim of this study was to evaluate the efficacy, safety, and tolerability of SHP465 mixed amphetamine salts (MAS) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods: This randomized, double-blind d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c5a673125632a91c1e32a8cdb6b668
http://europepmc.org/articles/PMC5771539
http://europepmc.org/articles/PMC5771539
Publikováno v:
CNS Drugs
Background SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc533ca6cab26b42bc73da8b33be4a2f
http://europepmc.org/articles/PMC5843702
http://europepmc.org/articles/PMC5843702